ArticleOccupational and environmental medicine2025
Atrazine use and markers of kidney function and nephrotoxicity among male farmers in the Biomarkers of Exposure and Effect in Agriculture Study.
Article in Occupational and environmental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence-Based Assessment of Pesticide-Related Nephrotoxicity: Clinical Outcomes, Experimental Data, and Molecular Signatures.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveAtrazine, an herbicide widely used in US agriculture, has been associated with kidney cancer and non-malignant kidney disease. However, the potential mechanisms underlying these associations remain unclear. We evaluated atrazine use and biomarkers of kidney function and nephrotoxicity among male farmers in the Biomarkers of Exposure and Effect in Agriculture Study.
methodsOur investigation included three groups of farmers defined based on atrazine use: (1) both recent (last 3 months) and past use (continuous users; n=83); (2) high lifetime use (≥178.5 lifetime days) but no recent use (former high users; n=88) and (3) never/low lifetime use (<50 lifetime days) and no recent use (never/low users; n=75). Biomarkers were measured in serum (creatinine, cystatin C, urea nitrogen, uric acid) and urine (kidney injury molecule-1 (KIM-1), albumin, creatinine). The 2021 CKD-EPI creatinine-cystatin C equation was used to calculate estimated glomerular filtration rate (eGFRcr-cys). We estimated the percentage difference (95% CI) in each marker across groups using multivariable linear regression.
resultsCompared with farmers with never/low atrazine use, continuous users had statistically significantly lower eGFRcr-cys (-9.4%; 95% CI -16.1% to -2.2%) and higher serum creatinine (9.4%; 95% CI: 1.6% to 17.9%) and cystatin C (10.8%; 95% CI 2.0% to 20.4%); no associations with these markers were observed for the former high users. We also observed higher uric acid for both former high and continuous users and lower urea nitrogen for former high users, although these associations were not statistically significant. Urine albumin-creatinine ratio and KIM-1 levels did not differ across groups.
conclusionsOur findings add to the evidence that continued atrazine use is associated with diminished kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.